In general, rating is an in depth analysis and evaluation in terms of quality and quantity. SciXess attaches great importance on performing their analyses - independently whether it is a matter of a company or a technology rating - unexceptionally under quantitative and qualitative aspects. We strongly believe that company and technology valuation is more than just attaching a price tag, it is a complex and voluntary process that ultimately depends on the experience of the conducting institution. SciXess®voluntarily binds itself to follow the strong principles of credit rating agencies as defined in the IOSCO’s "Code of Conduct Fundamentals for Credit Rating Agencies“ (International Organization of Securities Commissions) to guarantee:•Independency,•Objectivity,•Credibility, and•Disclosure of the complete rating / valuation process.
SciXess’ Biotech Business Valuation & Technology Rating services are designed to:•Help the management team to better understand their strategic options•Support you in generating profit from innovative technologies •Support investment decisions•Create real added value on a cost effective basis•Be a highly qualified source for a second opinion•Provide an independent and objective platform of experts’ knowledge •Provide relevant information about the market and the competitive environment of your technology or your (portfolio) company•Help you to achieve the best return on your investment
To offer our clients best quality company ratings, SciXess®expanded its analytical framework through a close collaboration with the renowned Rating-Services AG,R@S(Munich) (since 2010 part of F@S, Financial Services Ltd., London – Munich). As a pioneer in the rating of SMEs throughout all industries, as well as funds management companies (VC) and issuing houses. R@S is market leader and reports the highest number of ratings of small and medium-sized enterprises. Together with R@S, SciXess®developed the “Biotech Business ValuationTool”, an evaluation instrument that considers the characteristics of the Biopharmaceutical sector; amongst them the fact that R&D costs are substantial and that intellectual property is an important economic asset in this industry.